Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Taxane Resistance
Sara Maloney, Camden A. Hoover, Lorena V. Morejon-Lasso, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3323-3323
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Mechanisms of chemotherapy resistance in ovarian cancer
Mylena Ortiz, Emma Wabel, Kerry Mitchell, et al.
Cancer Drug Resistance (2022)
Open Access | Times Cited: 75
Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2144-2144
Open Access | Times Cited: 73
TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling
Xingkang Jiang, Shanqi Guo, Mengyao Xu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 71
The interactions of paclitaxel with tumour microenvironment
Ding‐Li Yu, Zhiping Lou, Fengyun Ma, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108555-108555
Closed Access | Times Cited: 66
Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
Mário Sousa‐Pimenta, Letı́cia M. Estevinho, Agnieszka Szopa, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 46
STIMULI-RESPONSIVE SUPRAMOLECULAR HYDROGELS FOR PACLITAXEL DELIVERY: PROGRESS AND PROSPECTS
Mohammad Qutub, Amol Tatode, Jayshree Taksande, et al.
Aspects of Molecular Medicine (2025) Vol. 5, pp. 100062-100062
Open Access | Times Cited: 1
Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities
Yichang Ren, Yuxi Wang, Gang Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 4498-4515
Closed Access | Times Cited: 80
The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators
Sepideh Mirzaei, Ali Zarrabi, Sholeh Etehad Asnaf, et al.
Life Sciences (2021) Vol. 268, pp. 119005-119005
Closed Access | Times Cited: 72
Platinum drugs and taxanes: can we overcome resistance?
Elena V. Sazonova, Gelina S. Kopeina, Evgeny N. Imyanitov, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 57
Chitosan: A versatile bio-platform for breast cancer theranostics
Vijay Sagar Madamsetty, Shima Tavakol, Saeid Moghassemi, et al.
Journal of Controlled Release (2021) Vol. 341, pp. 733-752
Closed Access | Times Cited: 55
PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
Shuo Deng, Hin Chong Leong, Arpita Datta, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1652-1652
Open Access | Times Cited: 48
Paclitaxel resistance related to nuclear envelope structural sturdiness
Elizabeth R. Smith, Jing‐Quan Wang, Dong‐Hua Yang, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100881-100881
Closed Access | Times Cited: 46
Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation
Muhammad Bilal Ahmed, Salman Ul Islam, Abdullah A. A. Alghamdi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15765-15765
Open Access | Times Cited: 45
Amyloid-beta and tau protein beyond Alzheimer’s disease
Morteza Abyadeh, Vivek Gupta, João A. Paulo, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 6, pp. 1262-1276
Open Access | Times Cited: 36
Autophagy in cancer resistance to paclitaxel: Development of combination strategies
Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114458-114458
Open Access | Times Cited: 33
Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
Vicenç Ruiz de Porras, Albert Font, Àlvaro Aytés
Cancer Letters (2021) Vol. 523, pp. 162-169
Closed Access | Times Cited: 44
Molecular mechanisms associated with chemoresistance in esophageal cancer
Matheus Lohan-Codeço, Maria Luísa Barambo-Wagner, Luiz Eurico Nasciutti, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 2
Open Access | Times Cited: 31
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
Annalisa Comandatore, Benoît Immordino, Rita Balsano, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 286-286
Open Access | Times Cited: 27
Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression
Fabrizio Fontana, Martina Anselmi, Patrízia Limonta
Cancers (2022) Vol. 14, Iss. 7, pp. 1614-1614
Open Access | Times Cited: 27
Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop
Xingkang Jiang, Yong Xu, Ranlu Liu, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 5, pp. 472-482
Open Access | Times Cited: 19
The circadian clock is disrupted in pancreatic cancer
Patrick B. Schwartz, Manabu Nukaya, Mark E. Berres, et al.
PLoS Genetics (2023) Vol. 19, Iss. 6, pp. e1010770-e1010770
Open Access | Times Cited: 16
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Astrid Hyldbakk, Karianne G. Fleten, Sofie Snipstad, et al.
Nanomedicine Nanotechnology Biology and Medicine (2023) Vol. 48, pp. 102656-102656
Open Access | Times Cited: 15
Exploiting epigenetic targets to overcome taxane resistance in prostate cancer
Buse Cevatemre, Ipek Bulut, Beyza Dedeoğlu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 6
Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies
Ylenia Cicirò, Denise Ragusa, Arturo Sala
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging
Mahima Chauhan, Sonali, Saurabh Shekhar, et al.
Biomaterials Advances (2024) Vol. 160, pp. 213833-213833
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top